Self-Funded With Spencer The "Silent Killer" Your Members Don't Know They Have
Nov 11, 2025
Mark Masson, President of Renalogic, dives into the alarming reality of chronic kidney disease (CKD), impacting 1 in 7 Americans, with 90% undiagnosed. He reveals how a duopoly inflates dialysis costs by 700-900% above Medicare rates. The discussion includes proactive management to slow CKD progression, the advantages of home dialysis, and the significant financial savings for employers through better intervention strategies. Mark emphasizes the critical need for early detection and competition within the healthcare market to tackle this silent killer.
AI Snips
Chapters
Transcript
Episode notes
CKD Is A Hidden, Widespread Risk
- One in seven Americans has chronic kidney disease and 90% are undiagnosed.
- Mark Masson calls CKD a "silent killer" because it often shows only at late stages.
Labs Can Miss Early CKD
- Routine labs often miss CKD until stage 4 because GFR can appear 'normal' earlier.
- This explains why many members remain undiagnosed until acute events push them into dialysis.
Catch And Treat CKD Early
- Get diagnosed and see the right specialists early to slow progression.
- Mark Masson recommends targeting CKD3 to "hold the line" and prevent ESRD.